4DMT is focused on the discovery and development of targeted, customized and proprietary next-generation AAV gene therapy products for use in patients with severe genetic diseases with high unmet medical need. Our robust discovery platform, termed Therapeutic Vector Evolution, empowers us to create customized gene delivery vehicles to deliver genes specifically to any tissue or organ in the body, by optimal clinical routes of administration, at lower doses and with resistance to pre-existing antibodies. These proprietary and targeted products allow us to treat both rare genetic diseases and complex large market diseases. 4DMT is creating a diverse and deep product pipeline through its own internal 4D products, as well as partnered programs.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/06/18 | $90,000,000 | Series B |
ArrowMark Partners Berkeley Catalyst Fund Chiesi Ventures CureDuchenne Ventures Janus Henderson Investors MiraeAsset Financial Group Pappas Capital Perceptive Advisors Pfizer Venture Investments Ridgeback Capital Management The Biotechnology Value Fund Viking Global Investors  | undisclosed |
